Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%. Analysts with Evercore ISI hailed the data as "transformational" in a note to investors.